Bohuslav Lázňovský, Výkladový slovníček na stranách 190-203, Poznámky pod čarou, Obsahuje bibliografické odkazy, and Converted from MODS to DC version 1.8 (EE patch 2018/05/24)
Primary graft dysfunction (PGD) is a life-threatening complication among heart transplant recipients and a major cause of early mortality. Although the pathogenesis of PGD is still unclear, ischemia/reperfusion injury has been identified as a predominant factor. Both necrosis and apoptosis contribute to the loss of cardiomyocytes during ischemia/reperfusion injury, and this loss of cells can ultimately lead to PGD. The aim of our prospective study was to find out whether cell death, necrosis and apoptosis markers present in the donor myocardium can predict PGD. The prospective study involved 64 consecutive patients who underwent orthotopic heart transplantation at our institute between September 2010 and January 2013. High-sensitive cardiac troponin T (hs-cTnT) as a marker of minor myocardial necrosis was detected from arterial blood samples before the donor’s pericardium was opened. Apoptosis (caspase-3, active + pro-caspase-3, bcl-2, TUNEL) was assessed from bioptic samples taken from the right ventricle prior graft harvesting. In our study, 14 % of transplant recipients developed PGD classified according to the standardized definition proposed by the ISHLT Working Group. We did not find differences between the groups in regard to hs-cTnT serum levels. The mean hs-cTnT value for the PGD group was 57.4±22.9 ng/l, compared to 68.4±10.8 ng/l in the group without PGD. The presence and severity of apoptosis in grafted hearts did not differ between grafts without PGD and hearts that subsequently developed PGD. In conclusion, our findings did not demonstrate any association between measured myocardial cell death, necrosis or apoptosis markers in donor myocardium and PGD in allograft recipients. More detailed investigations of cell death signaling pathways in transplanted hearts are required., O. Szarszoi, J. Besik, M. Smetana, J. Maly, M. Urban, J. Maluskova, A. Lodererova, L. Hoskova, Z. Tucanova, J. Pirk, I. Netuka., and Obsahuje bibliografii
Roztroušená skleróza je chronické onemocnění centrálního nervového systému neznámé etiologie s projevy autoimunitního zánětu a neurodegenerace. Onemocnění je heterogenní s nepředvídatelnou prognózou. Průběh choroby lze monitorovat klinickými parametry a sledováním vývoje patologických změn na magnetické rezonanci. I když máme znalosti o efektu nově zaváděných léků na základě klinických studií, není možné předvídat jejich účinnost u konkrétního pacienta. Proto se v posledních letech prosazuje snaha najít takové laboratorní markery, které by co možná nejspolehlivěji odpověděly na otázky spojené se subklinickou aktivitou onemocnění, jeho progresí a usnadnily terapeutické rozhodnutí na základě personifikované medicíny., Multiple sclerosis is a chronic disease of the central nervous system of unknown etiology with manifestations of autoimmune inflammation and neurodegeneration. The disease is heterogeneous with an unpredictable outcome. The course of the disease can be monitored with clinical parameters as well as pathological changes on magnetic resonance imaging. Even though the effects of newly introduced drugs are known from clinical trials, it is not possible to predict their efficacy in a specific patient. Therefore, efforts have intensified over the recent years to identify laboratory markers that would as reliably as possible answer questions on subclinical disease activity, its progression and would facilitate therapeutic decisions based personalized medicine. Key words. multiple sclerosis – therapy – biomarkers The author declare he has no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers., and J. Piťha
Biometric data are typically used for the purposes of unique identification of a person. However, recent research suggests that biometric data gathered for the purpose of identification can be analysed for extraction of additional information. This augments indicative value of biometric data. This paper illustrates the range of augmented indicative values of the data as well as identifies crucial factors that contribute to increased vulnerability of data subjects., Alžběta Krausová, Hananel Hazan, Ján Matejka., and Obsahuje bibliografické odkazy
Projekt Centra kompetence BIORAF se již třetím rokem zabývá biorafinačními procesy, které se zakládají na chemické, biologické a termické přeměně přírodních materiálů z odpadů rostlinného a živočišného původu ze zemědělské výroby i potravinářského průmyslu či z řas na žádané produkty s vysokou přidanou hodnotou. Projekt se řeší s finanční podporou Technologické agentury ČR za koordinace Ústavu chemických procesů AV ČR a ve spolupráci s Vysokou školou chemicko-technologickou, Botanickým ústavem AV ČR a společnostmi Agra, Rabbit, Briklis a Ecofuel. Viz také První rok Centra BIORAF a Aplikace biorafinací. and Olga Šolcová.
Biosimilární inzuliny jsou biologickými léky, jejichž účinek je podobný referenčním inzulinům. Průkaz bezpečnosti a účinnosti je hlavním požadavkem pro jejich klinické využití. Postupné zavedení do klinické praxe povede v budoucích letech zřejmě k většímu rozšíření, které si vyžádá dlouhodobé sledování i se zřetelem na ovlivnění glykemií a případné vedlejší účinky., Biosimilar insulins are biological drugs with the effect similar to reference insulins. Documented safety and efficacy are the main demand for their clinical utility. The subsequent introduction into clinical practice will be followed by more frequent use which will need longterm evaluation of their effect on glycemia and eventual side effects as well., and Jan Škrha
The Academy of Sciences of the Czech Republic (AS CR) established a new public research institution, the Institute of Biotechnology AS CR, v. v. i. The primary ambition of this new institute is to develop cutting-edge basic and oriented research on topics opening for diagnostic and therapeutic applicatons in human medicine. In particular, the institute was established to serve as a nucleation center of BIOCEV, the joined Biotech & Biomed Research Center of the Academy of Sciences with Charles University, to be built at Vestec near Prague by the year 2012 with the support of the European Regional Development Funds in frame of the Operational Program R&D for Innovation., Peter Šebo, -red-., and Tři otázky pro ředitele připravila -red-